Genetic mutation analysis for CDKN2A/CDK4 gene variants in whole blood
This test checks for changes (mutations) in the CDKN2A and CDK4 genes, which are linked to certain cancers and inherited conditions. It examines DNA from your blood to identify specific genetic variations that may increase cancer risk.
["This test helps assess inherited cancer risks by detecting gene mutations that could influence cancer development over time."]
Key facts at a glance
- LOINC
- 57927-6
- Short code
- CDKN2A-CDK4
- Synonyms
- CDKN2A+CDK4 gene Mut Anl Bld/T
- Category
- chemistry
- Sample
- whole-blood
- Container
- EDTA (lavender/purple-top) tube for whole blood; sterile container for tissue specimens
- Units
- N/A
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- 18–65 years
- Method
- molgen
- CPT
- 81479
- SNOMED
- 444923006
- Specimen volume
- 3-5 mL whole blood; tissue: minimum 5 mg fresh tissue or paraffin-embedded tissue block
- Stability
- Whole blood: 24 hours at room temperature, 7 days at 2-8°C; Tissue: formalin-fixed paraffin-embedded (FFPE) tissue stable indefinitely at room temperature; Fresh tissue: 24 hours at 2-8°C
- Hemolysis max
- 0
- Lipemia max
- 0
- Icterus max
- 0
- TAT
- 168–720 hours
- Order
- routine
Why This Test Might Be Ordered
Your healthcare provider may recommend this test if you have a family history of certain cancers, such as melanoma, pancreatic cancer, or other types linked to CDKN2A/CDK4 mutations. It may also be suggested if you have been diagnosed with a cancer linked to these genes or if you are part of a genetic counseling or cancer prevention program.
What to Expect Before the Test
No special preparation is needed. You will provide a small blood sample, usually drawn from your arm. The sample is processed to extract DNA for genetic analysis.
What the Test Results Mean
Results can be positive (mutation detected) or negative (no mutation found). A positive result indicates a genetic variation associated with increased cancer risk. Results are interpreted by a healthcare provider or genetic counselor in the context of your medical history and family background.
Common Conditions Linked to These Genes
Mutations in CDKN2A and CDK4 are linked to several hereditary cancers, including melanoma, pancreatic cancer, and certain types of sarcoma. These genes play a role in cell cycle regulation, and their mutations can increase the risk of developing cancer.
Reference range
Nominal result: Mutation Detected / Mutation Not Detected. Reference range is the absence of pathogenic CDKN2A and CDK4 gene mutations in healthy individuals without hereditary melanoma-pancreatic cancer syndrome.N/A
No fasting required. Informed consent is recommended prior to genetic testing. Genetic counseling prior to and following testing is advised. Patient should be informed about implications for family members and potential insurance/discrimination concerns (GINA protections).
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
◆Associated findings1
Short name
CDKN2A/CDK4 Mutation Test (Blood)
Frequently asked questions
What Does a Positive Test Result Mean?
Will This Test Show All Possible Cancer Risks?
Can I Get This Test Without a Doctor’s Order?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy